Zhang C - Search Results

1

A retrospective study on the efficacy and safety of Envafolimab, a PD-L1 inhibitor, in the treatment of advanced malignant solid tumors.

Zhang C, Li J, Wu H, Huang W, Da L, Shen Y, Sun G. Zhang C, et al. Front Pharmacol. 2024 Jan 31;15:1356013. doi: 10.3389/fphar.2024.1356013. eCollection 2024. Front Pharmacol. 2024. PMID: 38357311 Free PMC article.

2

Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors.

Huang N, Zhao C, Hu X, Zhang C, Xiong F, Huang W, Da L, Shen Y, Wu H. Huang N, et al. Among authors: zhang c. Transl Cancer Res. 2022 Jan;11(1):252-261. doi: 10.21037/tcr-22-54. Transl Cancer Res. 2022. PMID: 35261901 Free PMC article.

3

Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment.

Da L, Qu Z, Zhang C, Shen Y, Huang W, Zhang Y, Gu K. Da L, et al. Among authors: zhang c, zhang y. Front Oncol. 2023 Mar 23;13:1144875. doi: 10.3389/fonc.2023.1144875. eCollection 2023. Front Oncol. 2023. PMID: 37035159 Free PMC article.

4

Tumor Microenvironment Characteristics of Pancreatic Cancer to Determine Prognosis and Immune-Related Gene Signatures.

Zhang C, Ding J, Xu X, Liu Y, Huang W, Da L, Ma Q, Chen S. Zhang C, et al. Front Mol Biosci. 2021 Jun 8;8:645024. doi: 10.3389/fmolb.2021.645024. eCollection 2021. Front Mol Biosci. 2021. PMID: 34169093 Free PMC article.

5

Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.

Wu H, Huang N, Zhao C, Hu X, Da L, Huang W, Shen Y, Xiong F, Zhang C. Wu H, et al. Among authors: zhang c. Ann Transl Med. 2022 Mar;10(6):294. doi: 10.21037/atm-22-544. Ann Transl Med. 2022. PMID: 35433955 Free PMC article.

6

Effectiveness and safety of camrelizumab combined with chemotherapy in nonsquamous nonsmall cell lung cancer as the second-line therapy: A retrospective analysis.

Huang W, Zhang Q, Da L, Shen Y, Xiong F, Zhang C. Huang W, et al. Among authors: zhang c, zhang q. J Cancer Res Ther. 2022 Apr;18(2):576-580. doi: 10.4103/jcrt.jcrt_855_21. J Cancer Res Ther. 2022. PMID: 35645130 Free article.

7

Circular RNA circ_SETD2 represses breast cancer progression via modulating the miR-155-5p/SCUBE2 axis.

Shen Y, Zhang M, Da L, Huang W, Zhang C. Shen Y, et al. Among authors: zhang m, zhang c. Open Med (Wars). 2020 Sep 30;15(1):940-953. doi: 10.1515/med-2020-0223. eCollection 2020. Open Med (Wars). 2020. PMID: 33336052 Free PMC article.

8

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance.

Hu X, Chen W, Li F, Ren P, Wu H, Zhang C, Gu K. Hu X, et al. Among authors: zhang c. Front Oncol. 2023 Apr 28;13:1053125. doi: 10.3389/fonc.2023.1053125. eCollection 2023. Front Oncol. 2023. PMID: 37188174 Free PMC article.

9

Long Noncoding RNA PTPRG Antisense RNA 1 Reduces Radiosensitivity of Nonsmall Cell Lung Cancer Cells Via Regulating MiR-200c-3p/TCF4.

Ma Q, Niu R, Huang W, Da L, Tang Y, Jiang D, Xi Y, Zhang C. Ma Q, et al. Among authors: zhang c. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820942615. doi: 10.1177/1533033820942615. Technol Cancer Res Treat. 2020. PMID: 33174523 Free PMC article.

10

The PD-1 rs36084323 A > G polymorphism decrease cancer risk in Asian: A meta-analysis.

Da LS, Zhang Y, Zhang CJ, Bu LJ, Zhu YZ, Ma T, Gu KS. Da LS, et al. Pathol Res Pract. 2018 Nov;214(11):1758-1764. doi: 10.1016/j.prp.2018.09.015. Epub 2018 Sep 17. Pathol Res Pract. 2018. PMID: 30249505 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74,929 results

Search Page

Filters